Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double‐blind, placebo‐controlled study

Abstract

Rupatadine oral solution (1 mg/ml) was significantly more effective than placebo in reducing nasal symptoms at 4 and 6 wk and was well tolerated overall. This is the first large clinical report on the efficacy of an H1 receptor antagonist in children with PER in both symptoms and quality of life.

Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis

“…The statistic for inter-rater agreement on study eligibility was 0.65. In six trials some data were not fully reported and could not be extracted from the manuscript 23,27,28,29,30,31 , thus requiring their acquisition from graphs by digitization, otherwise authors or manufacturers were contacted to obtain raw data.…”

“…Following the exclusion of documents not related to the topic (review, different outcomes, not placebo controlled, open design, not randomized studies, different disease from AR, pharmacokinetics studies), 17 studies were assessed in full text for potential eligibility [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] . Finally 10 DBPC RCTs satisfied the inclusion criteria and entered the qualitative and quantitative analysis [23][24][25][26][27][28][29][30][31][32] (Figure 1). The statistic for inter-rater agreement on study eligibility was 0.65.…”

“…Each trial included a median of 266 participants (range: 30 to 543). The reflective assessment (registered every 12 or 24 hours) of overall allergy symptoms was available in eight trials (1650 patients) 23,25,[27][28][29][30][31][32] ; four trials performed an instantaneous assessment (757 patients) [24][25][26]32 . Data on individual nasal and ocular symptoms were available in seven trials 23,[27][28][29][30][31][32] .…”

“…The reflective assessment (registered every 12 or 24 hours) of overall allergy symptoms was available in eight trials (1650 patients) 23,25,[27][28][29][30][31][32] ; four trials performed an instantaneous assessment (757 patients) [24][25][26]32 . Data on individual nasal and ocular symptoms were available in seven trials 23,[27][28][29][30][31][32] . Six and five studies reported or permitted calculation of total nasal symptoms score in reflective 23,[27][28][29]31,32 and instantaneous [24][25][26]31,32 acquisition, respectively.…”

Update on Antihistamine Treatment for Chronic Urticaria in Children

“…The safety of rupatadine has been evaluated in randomized, double-blind, placebo-controlled studies in patients 12-65 years of age with chronic idi-opathic urticaria and in children 6-11 years of age with persistent allergic rhinitis [42][43][44].…”